Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Invested CapitalReturn on SalesTimes Interest Earned

Sanofi (SNY) EBIT Margin (2016 - 2026)

Sanofi's EBIT Margin history spans 16 years, with the latest figure at 20.18% for Q1 2026.

  • On a quarterly basis, EBIT Margin fell 291.0% to 20.18% in Q1 2026 year-over-year; TTM through Mar 2026 was 14.0%, a 697.0% decrease, with the full-year FY2025 number at 14.54%, down 311.0% from a year prior.
  • EBIT Margin hit 20.18% in Q1 2026 for Sanofi, down from 55.87% in the prior quarter.
  • Over the last five years, EBIT Margin for SNY hit a ceiling of 99.36% in Q4 2022 and a floor of 8.91% in Q4 2024.
  • Historically, EBIT Margin has averaged 26.51% across 5 years, with a median of 21.82% in 2022.
  • Biggest five-year swings in EBIT Margin: surged 8461bps in 2022 and later crashed -8320bps in 2023.
  • Tracing SNY's EBIT Margin over 5 years: stood at 99.36% in 2022, then plummeted by -84bps to 16.16% in 2023, then plummeted by -45bps to 8.91% in 2024, then skyrocketed by 527bps to 55.87% in 2025, then crashed by -64bps to 20.18% in 2026.
  • Business Quant data shows EBIT Margin for SNY at 20.18% in Q1 2026, 55.87% in Q4 2025, and 22.84% in Q3 2025.